Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX -1.92%35 Net Debt Paydown Yield % is -2.56% as of Jul. 17, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 623 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 68.7% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, PharmaCorp Rx's Net Debt Paydown Yield % was -2.56%.
PharmaCorp Rx (TSXV:PCRX) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
PharmaCorp Rx Net Debt Paydown Yield % Related Terms
PharmaCorp Rx Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx Net Debt Paydown Yield % Competitor Comparison
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx Net Debt Paydown Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -2.56% mean?
PharmaCorp Rx (TSXV:PCRX) has a Net Debt Paydown Yield % of -2.56% as of Jul. 17, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #428 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 68.7%.
Is PharmaCorp Rx's Net Debt Paydown Yield % too high?
PharmaCorp Rx's current Net Debt Paydown Yield % is -2.56%. Based on the distribution chart, PharmaCorp Rx ranks #428 out of 623 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's Net Debt Paydown Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #428 out of 623 companies for Net Debt Paydown Yield %. This places PharmaCorp Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Healthcare Providers & Services company?
A good Net Debt Paydown Yield % depends on the Healthcare Providers & Services industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on PharmaCorp Rx and its competitors. PharmaCorp Rx's current Net Debt Paydown Yield % is -2.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current Net Debt Paydown Yield % of -2.56%. The current Net Debt Paydown Yield % is -2.56%. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current Net Debt Paydown Yield % is -2.56% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
